Product image of Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate) supplied by GNH India

Neodolpasse

Active Ingredient:
Diclofenac Sodium, Orphenadrine Citrate
Origin:
EU

Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac sodium and orphenadrine citrate, the active ingredient in Neodolpasse, is a non‑steroidal anti‑inflammatory drug and muscle relaxant presented as a sterile injectable solution for intravenous use. It is used to manage moderate to severe pain, inflammatory conditions, and muscle spasm in adult patients.

GNH India supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Fresenius Kabi S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neodolpasse combines an NSAID and a muscle relaxant to address pain‑related pathways and spastic muscle conditions.

  • Moderate to severe pain: provides analgesia by reducing inflammation and relaxing skeletal muscle.
  • Inflammatory conditions: diminishes prostaglandin‑mediated swelling and discomfort.
  • Muscle spasm: alleviates involuntary muscle contractions through anticholinergic and NMDA‑receptor antagonism.

How It Works

  • Diclofenac sodium inhibits cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, lowering prostaglandin synthesis and thereby reducing inflammation and pain. Orphenadrine citrate acts as an anticholinergic agent and NMDA‑receptor antagonist, producing skeletal muscle relaxation and enhancing analgesic effects. The combined actions target both inflammatory mediators and neuromuscular excitability.

Side Effects

Adverse reactions may occur with any intravenous NSAID‑muscle‑relaxant combination.

Common Side Effects

  • Injection site pain or erythema
  • Nausea or dyspepsia
  • Dizziness or headache
  • Mild transient hypotension
  • Elevated liver enzymes
  • Dry mouth or blurred vision

Serious or Rare Side Effects

  • Severe gastrointestinal bleeding or ulceration
  • Anaphylactic or severe hypersensitivity reactions
  • Hepatotoxicity with marked transaminase rise
  • Renal impairment or acute kidney injury
  • Cardiac arrhythmias or myocardial infarction
  • Severe thrombocytopenia or coagulation disorders

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

  • Assess renal and hepatic function: adjust use in impairment.
  • Review cardiovascular history: NSAIDs may increase thrombotic risk.
  • Evaluate for gastrointestinal ulcer disease: consider gastro‑protective measures.
  • Screen for asthma or allergic reactions to NSAIDs.
  • Monitor for signs of bleeding or hematologic abnormalities.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Neodolpasse may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): increased bleeding risk.
  • Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.
  • Lithium: diclofenac may raise serum lithium levels.
  • Methotrexate: reduced clearance leading to toxicity.
  • ACE inhibitors or ARBs: heightened risk of renal impairment.

Moderate Interactions (Monitor Closely)

  • Diuretics: possible reduction in renal perfusion.
  • SSRIs or SNRIs: modest increase in bleeding tendency.
  • Corticosteroids: synergistic ulcerogenic effect.
  • Beta‑blockers: potential for additive hypotensive effect.
  • Anticholinergic drugs: may enhance dry‑mouth or blurred‑vision symptoms.

Frequently Asked Questions

Neodolpasse is indicated for the management of moderate to severe pain, inflammatory conditions such as arthritis or postoperative inflammation, and skeletal muscle spasm. It combines an NSAID with a muscle relaxant to address both pain and involuntary muscle contractions.

Diclofenac sodium inhibits COX‑1 and COX‑2 enzymes, reducing prostaglandin production and thereby decreasing inflammation and pain. Orphenadrine citrate acts as an anticholinergic and NMDA‑receptor antagonist, providing skeletal muscle relaxation. The dual mechanism offers analgesia and spasm relief.

The specific dose and infusion rate of Neodolpasse are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and response to therapy. Dosage should follow the prescriber’s instructions and local guidelines.

Safety data for Neodolpasse in pregnancy and lactation are limited. Diclofenac may affect fetal renal function, and orphenadrine can cross the placenta. Use only if the potential benefit justifies the potential risk, and consult a healthcare professional before administration.

To order Neodolpasse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable), and import documentation.

Neodolpasse uniquely combines diclofenac, a potent COX inhibitor, with orphenadrine, an anticholinergic muscle relaxant. Compared with other combinations, it offers both strong anti‑inflammatory action and targeted muscle relaxation in a single intravenous formulation, potentially reducing the need for multiple agents.

Neodolpasse should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain sterility and potency.

Neodolpasse is administered intravenously by a qualified healthcare professional. The solution is typically infused over a prescribed period, with the rate and total volume determined by the prescriber’s orders and patient monitoring.

Serious risks include severe gastrointestinal bleeding or ulceration, anaphylactic reactions, hepatotoxicity, renal impairment, and cardiovascular events such as myocardial infarction. Patients should be monitored closely for signs of these adverse events.

Neodolpasse is contraindicated in patients with known hypersensitivity to diclofenac, orphenadrine, or any component of the formulation, as well as those with active gastrointestinal bleeding, severe renal or hepatic impairment, and certain cardiovascular conditions. Clinicians should assess each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Diclofenac Sodium, Orphenadrine Citrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT